JP2024546654A - ポリペプチドモジュレーター - Google Patents

ポリペプチドモジュレーター Download PDF

Info

Publication number
JP2024546654A
JP2024546654A JP2024533810A JP2024533810A JP2024546654A JP 2024546654 A JP2024546654 A JP 2024546654A JP 2024533810 A JP2024533810 A JP 2024533810A JP 2024533810 A JP2024533810 A JP 2024533810A JP 2024546654 A JP2024546654 A JP 2024546654A
Authority
JP
Japan
Prior art keywords
disease
syndrome
polypeptide
cancer
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546654A5 (cg-RX-API-DMAC7.html
Inventor
クレイフ,サミル
ムクルティチャン,ミカエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgiamune Inc
Original Assignee
Georgiamune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgiamune Inc filed Critical Georgiamune Inc
Publication of JP2024546654A publication Critical patent/JP2024546654A/ja
Publication of JP2024546654A5 publication Critical patent/JP2024546654A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2024533810A 2021-12-10 2022-12-08 ポリペプチドモジュレーター Pending JP2024546654A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288330P 2021-12-10 2021-12-10
US63/288,330 2021-12-10
PCT/US2022/081186 WO2023108073A2 (en) 2021-12-10 2022-12-08 Polypeptide modulators

Publications (2)

Publication Number Publication Date
JP2024546654A true JP2024546654A (ja) 2024-12-26
JP2024546654A5 JP2024546654A5 (cg-RX-API-DMAC7.html) 2025-12-16

Family

ID=86731448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533810A Pending JP2024546654A (ja) 2021-12-10 2022-12-08 ポリペプチドモジュレーター

Country Status (10)

Country Link
US (1) US20250051419A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444339A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024546654A (cg-RX-API-DMAC7.html)
KR (1) KR20240118832A (cg-RX-API-DMAC7.html)
CN (1) CN118613277A (cg-RX-API-DMAC7.html)
AU (1) AU2022405109A1 (cg-RX-API-DMAC7.html)
CA (1) CA3241913A1 (cg-RX-API-DMAC7.html)
IL (1) IL313360A (cg-RX-API-DMAC7.html)
MX (1) MX2024006897A (cg-RX-API-DMAC7.html)
WO (1) WO2023108073A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026519808A (ja) * 2023-06-06 2026-06-18 ジョージアミューン・インコーポレイテッド 新規pd-l2変異体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000692A2 (en) * 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
US10260038B2 (en) * 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
CN106794235A (zh) * 2014-07-18 2017-05-31 阿德瓦希斯公司 用于引起抗肿瘤应答的基于李斯特菌的免疫原性组合物
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
US11219694B2 (en) * 2015-09-24 2022-01-11 The University Of North Carolina At Chapel Hill Methods and compositions for reducing metastases
CN118085109A (zh) * 2016-08-11 2024-05-28 昆士兰医学研究所理事会 免疫调节化合物
JP2020511144A (ja) * 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Pd−l2バリアント免疫調節タンパク質及びその使用
WO2019060888A1 (en) * 2017-09-25 2019-03-28 New York University HETÉRODIMÈRE-FC FUSION PROTEINS
US20210213063A1 (en) * 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3908600A1 (en) * 2019-01-11 2021-11-17 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Fusion protein with immunosuppressive activity

Also Published As

Publication number Publication date
WO2023108073A3 (en) 2023-10-19
CN118613277A (zh) 2024-09-06
EP4444339A2 (en) 2024-10-16
KR20240118832A (ko) 2024-08-05
CA3241913A1 (en) 2023-06-15
MX2024006897A (es) 2024-06-20
AU2022405109A1 (en) 2024-06-27
US20250051419A1 (en) 2025-02-13
WO2023108073A2 (en) 2023-06-15
IL313360A (en) 2024-08-01
EP4444339A4 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
JP7461350B2 (ja) Arg1及び/又はarg2の阻害剤
AU2020378282B2 (en) Dual IL-2R and IL-7R binding compounds
KR20230146528A (ko) 암을 치료하기 위한 방법
JP2022028750A (ja) Cd19に対するヒト化抗原結合ドメイン及び使用方法
TWI812918B (zh) IL-7Rαγc結合化合物
EP3494141A1 (en) Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
KR20210139312A (ko) Il-10 변이체 분자, 및 염증 질환 및 종양학의 치료 방법
JP7863349B2 (ja) ガンマデルタt細胞を刺激するための方法及び組成物
WO2015037000A1 (en) Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
EP3583113B1 (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma
JP2022507606A (ja) Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
EP4032907A9 (en) Bcma-targeted antibody and chimeric antigen receptor
JP2021512151A (ja) B7−h4抗体およびその使用方法
WO2016115218A1 (en) Antibody drug conjugates for the treatment of immune conditions
KR102669985B1 (ko) Btla 융합 단백질 작용제 및 이의 용도
US20250051419A1 (en) Polypeptide modulators
KR20260021697A (ko) 신규한 pd-l2 돌연변이체
HK40114371A (en) Polypeptide modulators
AU2016291846B2 (en) HIDE1 Compositions and Methods
WO2025133213A1 (en) Death receptor 5 (dr5)-armored car-t therapeutic
HK40021169B (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma
HK40021169A (en) Immunotherapeutic combinaton for the treatment of tgf alpha-expressing lung cancer or tgf alpha expressing melanoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251203